Introduction {#sec1}
============

The coronavirus disease-2019 (COVID-19) pandemic, caused by the beta-coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally and resulted in over 635,000 deaths as of July 24, 2020.\[[@bib1]\] Among patients with COVID-19, those with cancer have worse outcomes compared to those without underlying malignancy, but mortality rates differ significantly among studies, ranging from 3·7% to 61·5%.\[[@bib2], [@bib3]\].

Even larger studies have significantly different mortality rates -- for example a prospective observational cohort study from the UK reported a mortality rates of 35·4% (617 deaths among 1743 patients with COVID-19 and cancer),\[[@bib4]\] while the most recent update from the COVID-19 and Cancer Consortium (CCC-19) showed a death rate of 15·8%% (433 deaths in a cohort of 2,749 patients with both diseases).\[[@bib5]\].

Many of the studies reporting outcomes of patients with both cancer and COVID-19 to date have included relatively small numbers of such patients. Data related to this subpopulation is rapidly increasing, but is mostly fragmented. The aim of this systematic review and pooled analysis is to provide a more robust estimate of the mortality rate among SARS-CoV-2 infected patients with underlying cancer.

Methods {#sec2}
=======

Literature search {#sec2.1}
-----------------

A systematic literature review of PubMed, Google Scholar, MedRxiv, and conference proceedings from AACR, ASCO, ESMO 2020 up to July 16, 2020, was performed by two co-authors (KSS and MT) and disagreement was resolved by consensus with all authors. Multiple combinations of search terms were used: (COVID OR coronavirus OR SARS-CoV-2) AND (cancer OR tumor OR tumour OR malignancy OR malignancies OR neoplasia) AND (mortality OR death). The included study references were cross searched for additional studies. The duplicated reports were removed. The CCC-19 data was updated to reflect the keynote address at the AACR Virtual Meeting: Covid-19 and Cancer by Dr Solange Peters on July 21, 2020.

Study selection {#sec2.2}
---------------

Inclusion criteria were: i) Studies reporting mortality rate in cancer patients with COVID-19; ii) Any type of study (including retrospective studies, randomized controlled trials, prospective cohort studies, and case series); iii) Studies involving adults; iv) Studies published in English, Spanish, or French language.

Exclusion criteria: i) Studies with less than 10 patients with both cancer and COVID-19; ii) Studies reported in other languages than above mentioned.

Data extraction {#sec2.3}
---------------

Data were independently extracted by two authors (KSS and MT). Extracted data consisted of first author's name, type of publication (i.e. peer-reviewed, preprint, or conference proceeding), reported number of patients with cancer and COVID-19, number of deaths among the study population, study time period, institution or country involved, and type of cancer.

Statistical Analysis {#sec2.4}
--------------------

Primary endpoint was the case fatality rate (CFR), defined as rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI). Heterogeneity was assessed with the I^2^ test (substantial heterogeneity whenever I^2^ ≥50%). A sensitivity analysis was performed excluding reports including less than 100 patients.

Results {#sec3}
=======

Following the systematic literature search, 672 references (including 216 preprints) were retrieved, of which 598 were excluded on the basis of their titles and 32 on the basis of their abstract or full text due to various reasons (inclusion of pediatric patients, duplicated results, cohorts with less than 10 patients, studies not reporting number of deaths, studies not involving patients). In total 52 studies were included in this pooled analysis with a total of 18,650 patients with cancer and reporting 4,243 deaths ([Table 1](#tbl1){ref-type="table"} ).Table 1Mortality data from 52 studies on patients with cancer and COVID-19.Table 1S No.First AuthorType of studyTotal patients with cancer and COVID-19Deaths in patients with cancer and COVID-19Time periodInstitution or countryType of cancer1Burn et al.\[[@bib11]\]Preprint665613171 Mar to 6 May 2020Catalonia, SpainAny2Peters\[[@bib5]\]Conference proceedings274943317 Mar to 26 June 2020COVID-19 and Cancer Consortium (CCC-19), USA, Canada, SpainAny3Docherty et al.\[[@bib4]\]Peer-reviewed17436176 Feb to 19 Apr 2020UKAny4Fratino et al.\[[@bib12]\]Peer-reviewed909150Upto 30 Mar 2020ItalyAny5Lee et al.\[[@bib13]\]Peer-reviewed80022618 Mar to 26 Apr 2020UK Coronavirus Cancer Monitoring Project (UKCCMP)Any6Montopoli et al.\[[@bib14]\]Peer-reviewed43075Upto 1 Apr 202068 hospitals, Veneto, ItalyAny (but population restricted to males only)7Robilotti et al.\[[@bib15]\]Peer-reviewed4235110 Mar to 7 Apr 2020New York, USAAny8Horn et al.\[[@bib16]\]Conference proceedings40014126 Mar to 12 Apr 2020TERAVOLT Registry (8 countries)Thoracic cancers only9Miyashita et al.\[[@bib17]\]Peer-reviewed334371 Mar to 6 Apr 2020Mt Sinai Health System, New York, USAAny10Graselli et al.\[[@bib18]\]Peer-reviewed331202Upto 22 Apr 2020Lombardy, ItalyAny11Wang J et al.\[[@bib19]\]Preprint2835017 Dec 2019 to 18 Mar 2020Hubei, ChinaAny12COVIDSurg Collaborative\[[@bib20]\]Peer-reviewed239661 Jan to 31 Mar 202024 countriesAny (COVID was diagnosed based on lab, clinical, or radiological features)13Tian et al.\[[@bib21]\]Peer-reviewed2324613 Jan to 18 Mar 20209 hospitals in Wuhan, ChinaAny14Mehta et al.\[[@bib22]\]Peer-reviewed2186118 Mar to 8 Apr 2020New York, USAAny15Yang et al.\[[@bib23]\]Peer-reviewed2053013 Jan to 18 Mar 20209 hospitals from Hubei, ChinaAny16Pinato et al.\[[@bib24]\]Peer-reviewed20459Upto 6 Mar 20208 hospitals in UK, Italy, and SpainAny17Scarfo et al.\[[@bib25]\]Peer-reviewed1905528 Mar to 22 May 2020EuropeChronic lymphocytic leukemia only18De Melo et al.\[[@bib26]\]Preprint1816030 Apr to 26 May 2020Brazilian National Cancer InstituteAny19Martinez-Lopez et al.\[[@bib27]\]Preprint167561 Mar to 30 Apr 202073 hospitals in SpainMultiple Myeloma only20Russel et al.\[[@bib28]\]Preprint1563429 Feb to 12 May 2020Guys Hospital, London, UKAny21Basse et al.\[[@bib29]\]Preprint1412613 Mar to 25 Apr 2020Institute Curie Hospital, Paris, FranceAny22Barlesi et al.\[[@bib30]\]Conference proceedings1372014 Mar to 15 Apr 2020Gustave Roussy Cancer Campus, Villejuif, FranceAny23Angelis et al.\[[@bib31]\]Peer-reviewed113291 Mar to 30 Apr 2020Royal Marsden, London, UKAny24Gupta et al.\[[@bib32]\]Peer-reviewed112604 Mar to 4 Apr 202065 hospitals, USAAny25Zhang H et al.\[[@bib33]\]Peer-reviewed107235 Jan to 18 Mar 20205 hospitals from Wuhan, ChinaAny26Deng et al.\[[@bib34]\]Peer-reviewed1076Upto 11 Feb 2020ChinaAny27Dai et al.\[[@bib35]\]Peer-reviewed105121 Jan to 24 Feb 202014 hospitals from Hubei, ChinaAny28Luo et al.\[[@bib36]\]Peer-reviewed1022512 Mar to 6 May 2020New York, USALung cancer only29Hultcrantz et al.\[[@bib37]\]Preprint1001810 Mar to 30 Apr 2020New York, USAMultiple Myeloma only30Cook et al.\[[@bib38]\]Peer-reviewed7541Upto 18 May 2020UKMultiple Myeloma only31Booth et al.\[[@bib39]\]Peer-reviewed66341 Mar to 6 May 2020England, UKHematological malignancies only32Yarza et al.\[[@bib40]\]Peer-reviewed63169 Mar to 19 Apr 2020Hospital Universitario 12 de Octubre, Madrid, SpainAny33Assaad et al.\[[@bib41]\]Peer-reviewed5581 Mar to 25 Apr 2020Centre Léon Bérard, Paris, FranceAny34Wang B et al.\[[@bib42]\]Peer-reviewed58141 Mar to 30 Apr 2020New York, USAMultiple myeloma only35Gonzalez-Cao et al.\[[@bib43]\]Preprint50131 Apr to 17 May 2020SpainMelanoma only36Suleyman et al.\[[@bib44]\]Peer-reviewed49199 Mar to 27 Mar 2020Henry Ford Health System, Detroit, Michigan, USAAny37Rogado et al.\[[@bib45]\]Peer-reviewed45191 Feb to 7 Apr 2020Hospital Universitario Infanta Leonor of Madrid, SpainAny38Aries et al.\[[@bib46]\]Peer-reviewed351411 Mar to 11 May 2020Barts Cancer Centre, UKHematological malignancies only39Martin-Moro et al.\[[@bib47]\]Peer-reviewed34119 Mar to 17 Apr 2020Ramón y Cajal University Hospital, Madrid SpainHematological malignancies only40Zhang L et al.\[[@bib48]\]Peer-reviewed28813 Jan to 26 Feb 20203 hospitals in Wuhan, ChinaAny41Kalinski et al.\[[@bib2]\]Peer-reviewed27110 MaR to 29 Apr 2020Columbia University Irving Medical Center, USABreast cancer only42Joharatnam-Hogan et al.\[[@bib49]\]Preprint26612 Mar to 7 Apr 2020London, UKAny43Stroppa et al.\[[@bib50]\]Peer-reviewed25921 Feb to 18 Mar 2020Piacenza\'s general hospital, ItalyAny44Ciceri et al.\[[@bib51]\]Peer-reviewed221125 Feb to 24 Mar 2020San Raffaele Hospital, Lombardy, ItalyAny45Bogani et al.\[[@bib52]\]Peer-reviewed193Feb and Mar 2020Lombardy, ItalyAny46Guan et al.\[[@bib53]\]Peer-reviewed18311 Dec 2019 to 31 Jan 2020Wuhan, ChinaAny47Tagliamento et al.\[[@bib54]\]Peer-reviewed17410 Mar to 6 Apr 2020ItalySolid cancers48Wang L et al.\[[@bib55]\]Peer-reviewed1531 Jan to 6 Feb 2020Wuhan, ChinaAny49He et al.\[[@bib3]\]Peer-reviewed13823 Jan to 14 Feb 2020Union Hospital and Wuhan Central Hospital, ChinaHematological malignancies only50Lattenist et al.\[[@bib56]\]Peer-reviewed13613 Mar to 15 May 2020Universite´ catholique de Louvain, Brussels, BelgiumHematological malignancies only51Yu et al.\[[@bib57]\]Peer-reviewed12330 Dec 2019 to 17 Feb 2020Wuhan, ChinaAny52Wu et al.\[[@bib58]\]Peer-reviewed1149 Jan to 20 Mar 2020Hubei, ChinaAny, with prior exposure to immune checkpoint inhibitors

Pooled odds ratio (pOR) for mortality among patients with cancer and COVID-19 showed a mortality of 25·6% (95% CI 22·0% to 29·9%; I^2^=48·9%) ([Figure 1](#fig1){ref-type="fig"} ). A sensitivity analysis excluding reports with less than 100 patients showed an I^2^=49·7% for studies with ≥100 patients.Figure 1Forest plot of 52 studies reporting outcomes in patients with both cancer and COVID-19.Figure 1

Discussion {#sec4}
==========

The COVID-19 pandemic has had a major impact on patients with cancer,\[[@bib6]\] including a sharp reduction in cancer screening and the postponement of ongoing or planned therapy during the initial months of the pandemic, which could result in excess deaths from cancer in the future.\[[@bib7], [@bib8]\].

In order to restart standard cancer treatment protocols, it is important to quantify the risk of mortality among patients with both cancer and COVID-19, and data generated by large registries such as CCC-19 and Thoracic cancERs international coVid 19 cOLlaboraTion (TERAVOLT) could be valuable in this regard.\[[@bib9], [@bib10]\] Meta-analyses are also a useful tool to aggregate smaller datasets and estimate mortality risks in this vulnerable population.

The results of our pooled analysis clearly show that the mortality is high among patients with cancer and COVID-19, and should be considered as an independent risk factor, in addition to older age, male sex, black race, current smoker, other co-morbidities, etc. As more data becomes available, it is becoming increasingly clear that within the population of patients with both cancer and COVID-19, there are subsets with greater risk, such as patients with hematological malignancies or lung cancer, which needs deeper analysis.

Conclusions {#sec5}
===========

Patients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of infection with SARS-CoV-2 in patients with cancer, and to optimally manage those who do contract the infection.
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